Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Sucampo Pharmaceuticals, Inc. | exh_322.htm |
| EX-32.1 - EXHIBIT 32.1 - Sucampo Pharmaceuticals, Inc. | exh_321.htm |
| EX-31.2 - EXHIBIT 31.2 - Sucampo Pharmaceuticals, Inc. | exh_312.htm |
| EX-31.1 - EXHIBIT 31.1 - Sucampo Pharmaceuticals, Inc. | exh_311.htm |
| EX-23.1 - EXHIBIT 23.1 - Sucampo Pharmaceuticals, Inc. | exh_231.htm |
| EX-21 - EXHIBIT 21 - Sucampo Pharmaceuticals, Inc. | exh_21.htm |
| EX-12.1 - EXHIBIT 12.1 - Sucampo Pharmaceuticals, Inc. | exh_121.htm |
| EX-10.45 - EXHIBIT 10.45 - Sucampo Pharmaceuticals, Inc. | exh_1045.htm |
| EX-10.44 - EXHIBIT 10.44 - Sucampo Pharmaceuticals, Inc. | exh_1044.htm |
| 10-K - FORM 10-K - Sucampo Pharmaceuticals, Inc. | f10k_030817p.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Forms S-3 (333- 201566) and S-8 (No. 333-147420 and No. 333-213728) of Sucampo Pharmaceuticals, Inc. of our report dated March 9, 2015, except with respect to our opinion on the consolidated financial statements insofar as it relates to the change in composition of reportable segments discussed in Note 4 to the consolidated financial statements, as to which the date is May 6, 2015 relating to the financial statements and financial statement schedule, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
March 8, 2017